Results 251 to 260 of about 2,065,566 (311)

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

open access: yesMolecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder   +10 more
wiley   +1 more source

Life Evaluation of Bridges

open access: yesJournal of the Society of Mechanical Engineers, 1995
openaire   +2 more sources

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

open access: yesMolecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi   +14 more
wiley   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

open access: yesMolecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir   +13 more
wiley   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

open access: yesMolecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka   +9 more
wiley   +1 more source

The evaluation of life event data

Journal of Psychosomatic Research, 1994
Data from three life event studies are compared. The interviews covered events that occurred within a period of 2 years before interview. The same inventory was used in each of the studies. Samples were drawn from depressives, myocardial infarction patients and an industrial worker population.
S, Geyer   +4 more
openaire   +2 more sources

Quality-of-Life Evaluation in Diabetes

PharmacoEconomics, 1993
The diagnosis of diabetes and its subsequent management is likely to have a major impact on people's lives, in terms of both physical and psychological well-bei ng. Attainment of satisfactory d iabetic control (which is regarded as fundamental to the minimisalion of the tissue damage that occurs wi th increasi ng duration of disease) is more likely \0 ...
C, Eiser, J E, Tooke
openaire   +2 more sources

Home - About - Disclaimer - Privacy